The earnings call highlighted strong growth in strategic areas such as AI solutions, teleradiology services, and an expanding sales pipeline, alongside successful regulatory approvals. However, these positive developments are tempered by persistent net losses and challenges in revenue recognition from new installations.

Company Guidance -

Q2 2025

During the Q1 2025 earnings call, Nano-X Imaging Ltd. provided guidance on its commercial progress and future expectations. The company reported a GAAP net loss of $13.2 million for the quarter, with revenues reaching $2.8 million, a slight increase from $2.6 million in the same period last year. Nano-X's teleradiology services generated $2.6 million in revenue, showing an improved gross profit margin of approximately 17% on a GAAP basis. The company's AI solutions business saw revenue of $0.2 million, while the imaging systems and OEM services contributed $33,000. Nano-X aims to deploy over 100 ARC systems by the end of 2025, with most units expected in the US. The company is working towards achieving breakeven in its AI business by 2026 and in the ARC business by 2027, with an anticipated inflection point in the second half of 2025. The company's strategic efforts include enhancing its sales pipeline, expanding its market reach in the US and EU, and integrating AI into its medical imaging solutions to improve patient outcomes.

Strategic Acquisitions Driving Growth

The acquisitions of USARad and Nano-X AI have doubled revenues for USARad and transformed Nano-X AI from a pre-revenue business to a growing revenue stream.

Expanding Sales Pipeline

The sales pipeline has doubled since January 2025, with over 1,000 leads and a target of over 100 ARC systems in deployment stages by the end of 2025.

Regulatory Success

Received 510(k) clearance from the FDA for the Nano-X ARC systems, enabling wider deployment.

AI Solutions Momentum

Strong interest and expanding sales pipeline for AI solutions, including a partnership with Ezra AI for use in dozens of locations in the US.

Revenue Growth in Teleradiology

Revenue from teleradiology services increased to $2.6 million, with a gross profit margin of approximately 17% compared to 14% in the previous period.

Nano-X Imaging (NNOX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

NNOX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 12, 2025	2025 (Q2)	-0.19 / -	-0.23	―	―	―
May 22, 2025	2025 (Q1)	- / -	-0.21	―	―
Mar 31, 2025	2024 (Q4)	-0.19 / -0.21	-0.21	0.00% (0.00)	―
Nov 21, 2024	2024 (Q3)	-0.22 / -0.23	-0.37	37.84% (+0.14)	―
Aug 20, 2024	2024 (Q2)	-0.22 / -0.23	-0.31	25.81% (+0.08)	―
May 28, 2024	2024 (Q1)	- / -	-0.21	―	―
Apr 01, 2024	2023 (Q4)	-0.26 / -0.21	-0.21	0.00% (0.00)	―
Nov 28, 2023	2023 (Q3)	-0.30 / -0.37	-0.37	0.00% (0.00)	―
Aug 17, 2023	2023 (Q2)	-0.27 / -0.31	-0.38	18.42% (+0.07)	―
May 22, 2023	2023 (Q1)	-0.34 / -0.21	-0.41	48.78% (+0.20)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

NNOX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 22, 2025	$5.24	$5.24	0.00%
Mar 31, 2025	$5.23	$5.00	-4.40%
Nov 21, 2024	$5.89	$6.16	+4.58%
Aug 20, 2024	$7.24	$7.13	-1.52%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.